Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

ID DOID:50908
Name myelodysplastic syndrome
Definition A bone marrow cancer that is characterized by under production of white blood cells, red blood cells and platelets.
Source DiseaseOntology.org
Alt Ids
Path disease disease of cellular proliferation cancer organ system cancer hematologic cancer bone marrow cancer myelodysplastic syndrome

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
TP53 mutant N/A myelodysplastic syndrome not applicable detail...
NRAS G12X N/A myelodysplastic syndrome not applicable detail...
NRAS G13X N/A myelodysplastic syndrome not applicable detail...
NRAS Q61X N/A myelodysplastic syndrome not applicable detail...
IDH2 R140Q N/A myelodysplastic syndrome not applicable detail...
IDH2 R172X N/A myelodysplastic syndrome not applicable detail...
FLT3 exon 14 ins N/A myelodysplastic syndrome not applicable detail...
FLT3 D835X N/A myelodysplastic syndrome not applicable detail...
IDH2 R140X Enasidenib myelodysplastic syndrome predicted - sensitive detail...
IDH2 R172X Enasidenib myelodysplastic syndrome predicted - sensitive detail...
IDH2 R172X Azacitidine + Enasidenib myelodysplastic syndrome predicted - sensitive detail...
IDH2 R140X Azacitidine + Enasidenib myelodysplastic syndrome predicted - sensitive detail...
FLT3 exon 15 ins N/A myelodysplastic syndrome not applicable detail...
IDH1 mutant Ivosidenib myelodysplastic syndrome sensitive detail...
IDH1 R132C Ivosidenib myelodysplastic syndrome sensitive detail...
IDH1 R132G Ivosidenib myelodysplastic syndrome sensitive detail...
IDH1 R132H Ivosidenib myelodysplastic syndrome sensitive detail...
IDH1 R132L Ivosidenib myelodysplastic syndrome sensitive detail...
IDH1 R132S Ivosidenib myelodysplastic syndrome sensitive detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT00801489 Phase II Cytarabine + Filgrastim + Fludarabine + Gemtuzumab ozogamicin Cytarabine + Filgrastim + Fludarabine + Gemtuzumab ozogamicin + Idarubicin Fludarabine, Cytarabine, Filgrastim, Gemtuzumab Ozogamicin, and Idarubicin in Core Binding Factor (CBF) Leukemias Recruiting USA 0
NCT01028716 Phase II Filgrastim + Mycophenolate mofetil + Tacrolimus Cyclophosphamide + Fludarabine Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies Terminated USA 0
NCT01211457 Phase Ib/II Sapacitabine + Venetoclax Decitabine + Sapacitabine Study of Sapacitabine in Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes Unknown status USA 0
NCT01685411 Phase 0 Busulfan + Cyclophosphamide Filgrastim Allopurinol Mycophenolate mofetil anti-thymocyte globulin Tacrolimus Levetiracetam Busulfan and Cyclophosphamide Followed By ALLO BMT Terminated USA 0
NCT01773395 Phase II Busulfan + Fludarabine + Methotrexate + Tacrolimus Busulfan + Fludarabine + GVAX + Methotrexate + Tacrolimus GVAX vs. Placebo for MDS/AML After Allo HSCT Terminated USA 0
NCT01804101 Phase I CPX-351 Liposomal Cytarabine-Daunorubicin CPX-351 in Treating Patients With Untreated Myelodysplastic Syndrome or Acute Myeloid Leukemia Completed USA 0
NCT01822509 Phase I Ipilimumab + Nivolumab Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Transplant Completed USA 0
NCT01892371 Phase Ib/II Azacitidine + Quizartinib Cytarabine + Quizartinib Quizartinib With Azacitidine or Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Completed USA 0
NCT01898793 Phase Ib/II m-ceNK cells Aldesleukin + Cyclophosphamide + Fludarabine ALT-803 + Cyclophosphamide + Fludarabine Cytokine-induced Memory-like NK Cells in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) Terminated USA 0
NCT01915498 Phase Ib/II Enasidenib Phase 1/2 Study of Enasidenib (AG-221) in Adults With Advanced Hematologic Malignancies With an Isocitrate Dehydrogenase Isoform 2 (IDH2) Mutation Completed USA | FRA 0
NCT02019069 Phase II CPX-351 CPX-351 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Completed USA 0
NCT02115295 Phase II Cladribine + Cytarabine + Idarubicin Midostaurin Cladribine Plus Idarubicin Plus Cytarabine (ARAC) in Patients With Acute Myeloid Leukemia (AML), High Risk Myelodysplastic Syndrome (HR MDS) or Myeloid Blast Phase of Chronic Myeloid Leukemia (CML) Recruiting USA 0
NCT02117219 Phase I Azacitidine + Durvalumab Phase 1 Study to Evaluate MEDI4736 in MDS Completed USA | GBR | FRA | DEU 0
NCT02117297 Phase II Gemtuzumab ozogamicin SCT Plus Immune Therapy in Average Risk AML/MDS Completed USA 0
NCT02193958 Phase Ib/II FF-10501-01 Study of FF-10501-01 in Patients With Relapsed or Refractory Hematological Malignancies Completed USA 0
NCT02203903 Phase I MultiTAA-specific T cells Multi-institutional Prospective Research of Expanded Multi-antigen Specifically Oriented Lymphocytes for the Treatment of VEry High Risk Hematopoietic Malignancies (RESOLVE) Recruiting USA 0
NCT02221310 Phase II Busulfan + Cyclophosphamide + Gemtuzumab ozogamicin Immunochemotherapy and AlloSCT in Patients With High Risk CD33+ AML/MDS Completed USA 0
NCT02228525 Phase II Selinexor Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) in Patients With Myelodysplastic Syndromes Completed USA 0
NCT02240706 Phase II BI 836858 Phase I/II Trial to Investigate BI 836858 in Myelodysplastic Syndromes Terminated USA | DEU 0
NCT02250937 Phase II Cladribine Busulfan Busulfan + Venetoclax Fludarabine Venetoclax and Sequential Busulfan, Cladribine, and Fludarabine Phosphate Before Donor Stem Cell Transplant in Treating Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome Active, not recruiting USA 0
NCT02267863 Phase I APTO-253 A Study of APTO-253 in Patients With Relapsed or Refractory AML or MDS Terminated USA 0
NCT02269579 Phase II CPX-351 Pharmacokinetic and Pharmacodynamic Assessment of Treatment With CPX-351 (Cytarabine: Daunorubicin) Liposome for Injection in Acute Leukemias and MDS Patients With Moderate Hepatic Impairment Withdrawn USA 0
NCT02273102 Phase I Tranylcypromine + Tretinoin Phase 1 Study of TCP-ATRA for Adult Patients With AML and MDS (TCP-ATRA) Completed USA 0
NCT02281084 Phase II Azacitidine Azacitidine + Durvalumab Safety and Efficacy Study of CC-486 and Durvalumab in Subjects With Myelodysplastic Syndromes Completed USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS 1
NCT02367456 Phase Ib/II Azacitidine + Glasdegib A Combination Study of PF-04449913 (Glasdegib) and Azacitidine In 1st Line MDS, AML and CMML Patients Completed USA | GBR | FRA | DEU | CAN | BEL 0
NCT02462252 Phase II anti-thymocyte globulin + BKT140 + Cyclosporine + Methylprednisolone Phase IIA Open Label Study to Evaluate Efficacy and Safety of BL-8040 Followed by (hATG), Cyclosporine and Methyprednisolone in Adult Subjects With Aplastic Anemia or Hypoplastic Myelodysplastic Syndrome Completed USA 0
NCT02472145 Phase III Decitabine Decitabine + Talacotuzumab An Efficacy and Safety Study of Decitabine (DACOGEN) Plus Talacotuzumab (JNJ-56022473; Anti CD123) Versus Decitabine (DACOGEN) Alone in Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy Completed USA | GBR | FRA | ESP | DEU | BEL | AUS 7
NCT02477878 Phase I BPX-601 Rimiducid Study of Gene Modified Donor T Cell Infusion in Patients With Recurrent Disease After Allogeneic Transplant Active, not recruiting USA 0
NCT02487459 Phase I Rivogenlecleucel Rimiducid Safety Study of Gene Modified Donor T-Cells in Adults With Advanced Hematologic Malignancies Withdrawn USA 0
NCT02494167 Phase I MultiTAA-specific T cells Administration of Donor Multi TAA-Specific T Cells for AML or MDS (ADSPAM) Recruiting USA 0
NCT02498665 Phase I DSP-7888 A Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies Completed USA 0
NCT02508870 Phase I Azacitidine Atezolizumab A Safety and Pharmacology Study of Atezolizumab (MPDL3280A, Anti-PD-L1 Antibody) Administered Alone or in Combination With Azacitidine in Patients With Myelodysplastic Syndromes Completed USA 0
NCT02530034 Phase I Hu8F4 Hu8F4 in Treating Patients With Advanced Hematologic Malignancies Active, not recruiting USA 0
NCT02530463 Phase II Nivolumab Azacitidine Ipilimumab Nivolumab and Ipilimumab With 5-azacitidine in Patients With Myelodysplastic Syndromes (MDS) Active, not recruiting USA 0
NCT02543879 Phase I FT-1101 Azacitidine + FT-1101 Study of a Novel BET Inhibitor FT-1101 in Patients With Relapsed or Refractory Hematologic Malignancies Completed USA 0
NCT02553941 Phase I Azacitidine + Ibrutinib Ibrutinib and Azacitidine for Treatment of Higher Risk Myelodysplastic Syndrome Completed USA 0
NCT02556931 Phase II Cyclophosphamide + Fludarabine + Melphalan + Tacrolimus Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies Completed USA 0
NCT02562443 Phase III Rigosertib Sodium Controlled Study of Rigosertib Versus Physician's Choice of Treatment in MDS Patients After Failure of an HMA (INSPIRE) Terminated USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS 12
NCT02564536 Phase I Decitabine + Pacritinib Pacritinib in Combination With Low Dose Decitabine in Intermediate-High Risk Myelofibrosis or Myeloproliferative Neoplasm (MPN)/Myelodysplastic Syndrome (MDS) Withdrawn 0
NCT02576301 Phase Ib/II Combretastatin A1 Diphosphate Combretastatin A1 Diphosphate + Cytarabine Dose Escalation of OXi4503 as Single Agent and Combination With Cytarabine w/Subsequent Ph 2 Cohorts for AML and MDS Unknown status USA 0
NCT02598661 Phase III Imetelstat Study to Evaluate Imetelstat (JNJ-63935937) in Subjects With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) Active, not recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL 9
NCT02610777 Phase II Azacitidine MLN4924 An Efficacy and Safety Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine in Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML) and Low-Blast Acute Myelogenous Leukemia (AML) Completed USA | ITA | FRA | ESP | DEU | CAN | BEL 5
NCT02641002 Phase I CC-90002 A Study of CC-90002 in Subjects With Acute Myeloid Leukemia (AML) and High-risk Myelodysplastic Syndrome (MDS) Terminated USA 0
NCT02666950 Phase II Adavosertib Cytarabine WEE1 Inhibitor AZD1775 With or Without Cytarabine in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome Completed USA 0
NCT02676323 Phase Ib/II Cytarabine + Fludarabine + Leucovorin + Panobinostat Panobinostat With Fludarabine and Cytarabine for Treatment of Children With Acute Myeloid Leukemia or Myelodysplastic Syndrome Terminated USA 0
NCT02677922 Phase Ib/II Azacitidine + Ivosidenib Azacitidine Azacitidine + Enasidenib A Study to Assess the Safety and Efficacy of Two Combinations of Isocitrate Dehydrogenase (IDH) Mutant Targeted Therapies Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) Harboring IDH Mutations Who Are Not Candidates to Receive Intensive Induction Chemotherapy Active, not recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS 5
NCT02683395 Phase I PLX51107 A Study of PLX51107 in Advanced Malignancies Terminated USA 0
NCT02684162 Phase II Guadecitabine SGI-110 With Donor Lymphocyte Infusion (DLI) for Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS) Relapsing Post Allogeneic Stem Cell Transplantation (AlloSCT) Active, not recruiting USA 0
NCT02717884 Phase Ib/II Cytarabine + Tranylcypromine + Tretinoin Study of Sensitization of Non-M3 AML Blasts to ATRA by Epigenetic Treatment With Tranylcypromine (TCP) (TRANSATRA) Unknown status DEU 0
NCT02719574 Phase I Cytarabine + Olutasidenib Olutasidenib Azacitidine + Olutasidenib Open-label Study of FT-2102 With or Without Azacitidine or Cytarabine in Patients With AML or MDS With an IDH1 Mutation Completed USA | ITA | GBR | FRA | ESP | DEU | CAN | AUS 1
NCT02721875 Phase I Azacitidine Volasertib Trial of Volasertib With or Without Azacitidine in Patients With Myelodysplastic Syndromes Terminated 1
NCT02722668 Phase II Cyclophosphamide + Fludarabine + Mycophenolate mofetil Sirolimus anti-thymocyte globulin UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep Active, not recruiting USA 0
NCT02724163 Phase III Gemtuzumab ozogamicin Busulfan + Fludarabine Cytarabine Cytarabine + Fludarabine Cytarabine + Daunoxome Busulfan + Cyclophosphamide Cytarabine + Mitoxantrone International Randomised Phase III Clinical Trial in Children With Acute Myeloid Leukaemia (Myechild01) Recruiting GBR | FRA | AUS 3
NCT02727803 Phase II anti-thymocyte globulin + Fludarabine + haNK cells + Melphalan anti-thymocyte globulin + Cyclophosphamide + Fludarabine + haNK cells + Rituximab anti-thymocyte globulin + Busulfan + Clofarabine + Fludarabine + haNK cells Personalized NK Cell Therapy in CBT Recruiting USA 0
NCT02728050 Phase Ib/II Sorafenib Cladribine + Cytarabine + Filgrastim + Mitoxantrone Filgrastim, Cladribine, Cytarabine and Mitoxantrone With or Without Sorafenib Tosylate in Treating Patients With Newly-Diagnosed, High-Risk Acute Myeloid Leukemia or Myelodysplastic Syndrome Completed USA 0
NCT02743611 Phase I Rimiducid BPX-701 Dose Finding Study Evaluating Safety and Feasibility in Patients With Relapsed or Refractory Myeloid Neoplasms Terminated USA 0
NCT02749708 Phase Ib/II IRX5183 Study of IRX5183 in Relapsed and Refractory Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome Terminated USA 0
NCT02756572 Phase I Sirolimus Mycophenolate mofetil Cyclosporine Cytarabine Melphalan Cladribine Filgrastim mitoxantrone hydrochloride Fludarabine Early Allogeneic Hematopoietic Cell Transplantation in Treating Patients With Relapsed or Refractory High-Grade Myelodysplastic Syndrome or Acute Myeloid Leukemia Completed USA 0
NCT02775903 Phase II Azacitidine Azacitidine + Durvalumab An Efficacy and Safety Study of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects With Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly Subjects With Acute Myeloid Leukemia (AML) Completed USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT 3
NCT02779777 Phase II Tipifarnib Tipifarnib in Subjects With Transfusion-dependent, Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes Terminated USA 0
NCT02786485 Phase I Rimiducid Rivogenlecleucel Study of Matched Unrelated Donor T Cell Infusion for Hematologic Malignancies After Allo-HSCT Withdrawn 0
NCT02790515 Phase II Sirolimus anti-thymocyte globulin Blinatumomab Tacrolimus Thiotepa Melphalan Fludarabine Cyclophosphamide Mesna Rituximab Filgrastim Provision of TCR?? T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation Recruiting USA 0
NCT02793544 Phase II Cyclophosphamide Busulfan Sirolimus Mycophenolate mofetil Mesna Fludarabine HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide Completed USA 0
NCT02795520 Phase Ib/II OTS167 Pharmacological Study of Intravenous OTS167 in Patients With Refractory or Relapsed Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Advanced Myelodysplastic Syndromes, Advanced Myeloproliferative Neoplastic Disorders, or Advanced Chronic Myelogenous Leukemia Terminated USA 0
NCT02807558 Phase II Azacitidine + Tamibarotene Tamibarotene A Biomarker-Directed Phase 2 Trial of SY-1425 in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Completed USA | FRA 0
NCT02829840 Phase Ib/II Azacitidine + Ponatinib Dose-Escalation Study of Ponatinib, a FLT3 Inhibitor, With and Without Combination of 5-Azacytidine, in Patients With FLT3-Mutated Acute Myeloid Leukemia (AML) Withdrawn 0
NCT02841540 Phase I H3B-8800 A Phase 1 Study to Evaluate H3B-8800 in Participants With Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia Terminated USA | ITA | FRA | ESP | BEL 2
NCT02846376 Phase I Ipilimumab Ipilimumab + Nivolumab Nivolumab Single Agent and Combined Inhibition After Allogeneic Stem Cell Transplant (CPIT-002) Terminated USA 0
NCT02848001 Phase I CC-90009 A Dose-finding Study of CC-90009 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-risk Myelodysplastic Syndromes Active, not recruiting USA | GBR | FRA | ESP | CAN 1
NCT02890329 Phase I Decitabine + Ipilimumab Ipilimumab and Decitabine in Treating Patients With Relapsed or Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia Active, not recruiting USA 0
NCT02890758 Phase I ALT-803 Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT803 Completed USA 0
NCT02907359 Phase III Cytarabine Guadecitabine Guadecitabine (SGI-110) vs Treatment Choice in Adults With MDS or CMML Previously Treated With HMAs Completed USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL 6
NCT02909972 Phase I ALRN-6924 + Cytarabine ALRN-6924 Safety Study of ALRN-6924 in Patients With Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome Completed USA 0
NCT02923986 Phase Ib/II BP1001 + Dasatinib Clinical Trial of BP1001 (Liposomal Grb2 Antisense Oligonucleotide) in Combination With Dasatinib in Patients With Ph + CML Who Have Failed TKI, Ph+ AML, Ph+ MDS Withdrawn USA 0
NCT02935361 Phase Ib/II Atezolizumab + Guadecitabine Guadecitabine and Atezolizumab in Treating Patients With Advanced Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia That Is Refractory or Relapsed Active, not recruiting USA 0
NCT02936752 Phase I Entinostat + Pembrolizumab Entinostat and Pembrolizumab in Treating Patients With Myelodysplastic Syndrome After DNMTi Therapy Failure Active, not recruiting USA 0
NCT02942290 Phase II Azacitidine Azacitidine + Venetoclax A Study Evaluating Venetoclax in Combination With Azacitidine Compared With Azacitidine Alone in Participants With Previously Untreated Higher-Risk Myelodysplastic Syndromes (MDS) Active, not recruiting USA | ITA | GBR | FRA | DEU | CAN | AUS 0
NCT02960646 Phase I Fludarabine + Melphalan CD45RA-depleted donor lymphocytes Cyclophosphamide Tacrolimus Rituximab Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies Completed USA 0
NCT02966782 Phase I Azacitidine + Venetoclax Venetoclax A Study Evaluating Venetoclax Alone and in Combination With Azacitidine in Subjects With Higher-Risk Myelodysplastic Syndromes (MDS) After Hypomethylating Agent-Failure Completed USA | DEU | AUS 0
NCT02979366 Phase I MIK665 Phase I Study of S64315 Administred Intravenously in Patients With Acute Myeloid Leukaemia or Myelodysplastic Syndrome Completed USA | FRA | ESP | AUS 0
NCT02981914 Phase 0 Pembrolizumab Pilot Study of Pembrolizumab Treatment for Disease Relapse After Allogeneic Stem Cell Transplantation Recruiting USA 0
NCT02989844 Phase II ALT-803 QUILT-3.035: Relapse Prophylaxis With ALT-803 for AML and MDS Pts Following Allo HSCT Completed USA 0
NCT03011034 Phase II Talacotuzumab Daratumumab Study to Separately Evaluate the Activity of Talacotuzumab (JNJ-56022473) or Daratumumab in Transfusion-Dependent Participants With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) Who Are Relapsed or Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment Completed USA | ITA | ESP | BEL 2
NCT03018405 Phase Ib/II NKR-2 cells A Dose Escalation Phase I Study to Assess the Safety and Clinical Activity of Multiple Cancer Indications (THINK) Unknown status USA | BEL 0
NCT03042689 Phase I Regorafenib Study of Regorafenib in Patients With Advanced Myeloid Malignancies Completed USA 0
NCT03047993 Phase Ib/II Azacitidine + Telaglenastat Glutaminase Inhibitor CB-839 and Azacitidine in Treating Patients With Advanced Myelodysplastic Syndrome Completed USA 0
NCT03066648 Phase I Decitabine + Spartalizumab Decitabine + Sabatolimab + Spartalizumab Decitabine + Sabatolimab Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDS Completed USA | GBR | FRA | ESP | DEU | AUS 2
NCT03067571 Phase II Daratumumab Daratumumab in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome Terminated USA 0
NCT03069469 Phase I Vimseltinib Study of DCC-3014 in Patients With Advanced Malignancies Active, not recruiting USA | ITA | GBR | FRA | ESP | CAN | AUS 2
NCT03072043 Phase Ib/II APR-246 + Azacitidine Phase 1b/2 Safety and Efficacy of APR-246 w/Azacitidine for tx of TP53 Mutant Myeloid Neoplasms Completed USA 0
NCT03074006 Phase Ib/II Vactosertib Dose Escalation and Proof-of-Concept Studies of TEW-7197 Monotherapy in Patients With Myelodysplastic Syndrome (MDS) Completed USA 0
NCT03075826 Phase II Guadecitabine A Phase II Study of SGI-110 in Philadelphia-Negative Myeloproliferative Neoplasms Completed USA 0
NCT03092674 Phase II Cytarabine + Decitabine Azacitidine + Midostaurin Decitabine Azacitidine + Nivolumab Azacitidine Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome Active, not recruiting USA 0
NCT03094637 Phase II Azacitidine + Pembrolizumab Azacitidine and Pembrolizumab for Patients With Myelodysplastic Syndrome (MDS) Active, not recruiting USA 0
NCT03113643 Phase I Azacitidine + Tagraxofusp-erzs + Venetoclax Azacitidine + Tagraxofusp-erzs SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Recruiting USA 0
NCT03128034 Phase Ib/II Cyclosporine + Fludarabine + Mycophenolate mofetil + Sirolimus 211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome Suspended USA 0
NCT03151304 Phase II Azacitidine + Pracinostat Azacitidine A Safety and Efficacy Study of Pracinostat and Azacitidine in Patients With High Risk Myelodysplastic Syndromes Terminated USA 0
NCT03164057 Phase II Etoposide Filgrastim Dexrazoxane Daunorubicin Idarubicin Fludarabine Asparaginase Cytarabine Sorafenib Mitoxantrone Decitabine Azacitidine A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia Active, not recruiting USA 0
NCT03187288 Phase I CFI-400945 A Study of CFI-400945 Fumarate in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Active, not recruiting CAN 0
NCT03214562 Phase Ib/II Venetoclax Cytarabine + Filgrastim + Fludarabine + Idarubicin + Venetoclax Study of the BCL-2 Inhibitor Venetoclax in Combination With Standard Intensive Acute Myeloid Leukemia (AML) Induction/Consolidation Therapy With FLAG-IDA in Patients With Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia (AML) Recruiting USA 0
NCT03214666 Phase Ib/II GTB-3550 TriKE GTB-3550 Tri-Specific Killer Engager (TriKE®) for High Risk Hematological Malignancies Terminated USA 0
NCT03238248 Phase II Azacitidine + MLN4924 Pevonedistat and Azacitidine in MDS or MDS/MPN Patients Who Fail Primary Therapy With DNA Methyl Transferase Inhibitors Active, not recruiting USA 0
NCT03248479 Phase I Azacitidine + Hu5F9-G4 Hu5F9-G4 Hu5F9-G4 Monotherapy or Hu5F9-G4 in Combination With Azacitidine in Patients With Hematological Malignancies Terminated USA | GBR 0
NCT03263637 Phase I AZD4573 Study to Assess Safety, Tolerability, Pharmacokinetics and Antitumor Activity of AZD4573 in Relapsed/Refractory Haematological Malignancies Completed GBR | DEU 1
NCT03268954 Phase III Azacitidine + MLN4924 Azacitidine Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML) (PANTHER) Active, not recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS 11
NCT03286114 Phase I Pembrolizumab Augmentation of the Graft vs. Leukemia Effect Via Checkpoint Blockade With Pembrolizumab Terminated USA 0
NCT03306264 Phase III Decitabine Decitabine and Cedazuridine Study of ASTX727 vs IV Decitabine in MDS, CMML, and AML Completed USA | ITA | GBR | FRA | ESP | DEU | CAN | AUT 2
NCT03326310 Phase I Azacitidine + Selumetinib Study of MEK Inhibitor Selumetinib in Combination With Azacitidine in Patients With Higher Risk Chronic Myeloid Neoplasia Recruiting USA 0
NCT03326921 Phase I Fludarabine HA-1 TCR T cells HA-1 T TCR T Cell Immunotherapy for the Treating of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant Suspended USA 0
NCT03358719 Phase I Decitabine + Nivolumab + Poly ICLC + Rasdegafusp alfa DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, Decitabine, and Nivolumab in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia Completed USA 0
NCT03359460 Phase I Ibrutinib + Lenalidomide Ibrutinib and Lenalidomide in Treating Patients With Myelodysplastic Syndrome Completed USA 0
NCT03383575 Phase II Azacitidine + Enasidenib Enasidenib Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome Recruiting USA 0
NCT03386513 Phase Ib/II IMGN632 Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCN Active, not recruiting USA | ITA | GBR | FRA | ESP | DEU 0
NCT03393611 Phase I anti-thymocyte globulin + Fludarabine + Melphalan CPX-351 CPX-351 Salvage Therapy Followed by Haplo-Cord Transplant for Relapsed/Refractory Leukemia or Myelodysplastic Syndrome Completed USA 0
NCT03397173 Phase II Azacitidine + Vitamin C TET2 Mutations in Myelodysplastic Syndromes and Acute Myeloid Leukemia With Azacitidine + Ascorbic Acid Completed USA 0
NCT03404193 Phase II Decitabine + Venetoclax Venetoclax in Combination With 10-Day Decitabine in Newly Diagnosed Elderly or Relapsed/Refractory Acute Myeloid Leukemia and Relapsed High-risk Myelodysplastic Syndrome Active, not recruiting USA 0
NCT03404726 Phase I BAY2402234 A Study to Investigate BAY2402234, a Dihydroorotate Dehydrogenase (DHODH) Inhibitor, in Myeloid Malignancies Terminated USA | FRA 0
NCT03417154 Phase II Cyclophosphamide + Nivolumab Nivolumab and Oral Cyclophosphamide for R/R AML and HIgh Risk MDS Completed USA 0
NCT03459859 Phase I Cytarabine + MLN4924 Pevonedistat and Low Dose Cytarabine in Adult Patients With AML and MDS Completed USA 0
NCT03465540 Phase I AMG 397 + Azacitidine AMG 397 + Dexamethasone AMG 397 Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With Selected Relapsed or Refractory Hematological Malignancies Terminated USA | ITA | FRA | AUS 2
NCT03471260 Phase Ib/II Azacitidine + Ivosidenib + Venetoclax Ivosidenib + Venetoclax Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies Recruiting USA 0
NCT03480360 Phase III Cyclophosphamide + Fludarabine Filgrastim + Mycophenolate mofetil + Tacrolimus Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression Active, not recruiting USA 0
NCT03503409 Phase II Ivosidenib IDH1 (AG 120) Inhibitor in Patients With IDH1 Mutated Myelodysplastic Syndrome Recruiting ITA | FRA 0
NCT03503968 Phase Ib/II MDG1011 TCR Modified T Cells MDG1011 in High Risk Myeloid and Lymphoid Neoplasms Terminated DEU 0
NCT03515512 Phase I Enasidenib IDH2 Inhibition Using Enasidenib as Maintenance Therapy for IDH2-mutant Myeloid Neoplasms Following Allogeneic Stem Cell Transplantation Completed USA 0
NCT03516591 Phase I AMV-564 A Phase 1 Study of AMV564 in Patients With Intermediate or High-Risk Myelodysplastic Syndromes Completed USA 0
NCT03531736 Phase I Rituximab Cyclophosphamide + Fludarabine T Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation Conditioned With a Reduced Intensity Regimen in Patients With Hematologic Malignancies and Aplastic Anemia Active, not recruiting USA 0
NCT03537599 Phase Ib/II Daratumumab Daratumumab and Donor Lymphocyte Infusion in Treating Participants With Relapsed Acute Myeloid Leukemia After Stem Cell Transplant Completed USA 0
NCT03564821 Phase I Ivosidenib IDH1 Inhibition Using Ivosidenib as Maintenance Therapy for IDH1-mutant Myeloid Neoplasms Following Allogeneic Stem Cell Transplantation Completed USA 0
NCT03572764 Phase I CPX-351 CPX-351 (Vyxeos) for Transplant Eligible, Higher Risk Patients With Myelodysplastic Syndrome Active, not recruiting USA 0
NCT03573310 Phase I JNJ-64619178 A Study of JNJ-64619178, an Inhibitor of PRMT5 in Participants With Advanced Solid Tumors, NHL, and Lower Risk MDS Active, not recruiting USA | ESP | DEU | CAN 1
NCT03594955 Phase Ib/II SAR440234 First in Human Testing of Dose-escalation of SAR440234 in Patients With Acute Myeloid Leukemia, Acute Lymphoid Leukemia and Myelodysplastic Syndrome Terminated USA | FRA 0
NCT03603964 Phase II Guadecitabine Guadecitabine Extension Study Terminated USA | ITA | ESP | CAN | AUT 4
NCT03613532 Phase I Azacitidine + Venetoclax Busulfan + Fludarabine + Venetoclax Decitabine and Cedazuridine Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPN Recruiting USA 0
NCT03614728 Phase I Azacitidine + GSK3326595 GSK3326595 Study to Investigate the Safety and Clinical Activity of GSK3326595 and Other Agents to Treat Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) Terminated USA | CAN 0
NCT03661307 Phase Ib/II Decitabine + Quizartinib + Venetoclax Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome Recruiting USA 0
NCT03670966 Phase Ib/II BC8-B10 + Cyclophosphamide + Fludarabine Cyclophosphamide + Filgrastim + Mycophenolate mofetil + Sirolimus + Tacrolimus 211At-BC8-B10 and Donor Stem Cell Transplant in Treating Relapsed or Refractory AML, ALL, or Myelodysplastic Syndrome Recruiting USA 0
NCT03672539 Phase I Gemtuzumab ozogamicin CPX-351 + Gemtuzumab ozogamicin Liposome-encapsulated Daunorubicin-Cytarabine and Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome Recruiting USA 0
NCT03674411 Phase II Busulfan + Filgrastim + Fludarabine + Melphalan + MGTA-456 + Mycophenolate mofetil + Tacrolimus Cyclophosphamide + Filgrastim + Fludarabine + MGTA-456 + Mycophenolate mofetil + Tacrolimus Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy Active, not recruiting USA 0
NCT03699475 Phase II Rimiducid + Rivogenlecleucel Cyclophosphamide Study of Haplo-HSCT + BPX-501 vs Haplo-HSCT + Post Transplant Cyclophosphamide in Patients With AML or MDS (THRIVE) Terminated USA 0
NCT03735446 Phase I Cytarabine + Etoposide + Mitoxantrone + Prexasertib Prexasertib in Combination With MEC in Relapsed/Refractory AML and High Risk MDS - a Phase I Trial Terminated USA 0
NCT03744390 Phase II Enasidenib IDH2 (AG 221) Inhibitor in Patients With IDH2 Mutated Myelodysplastic Syndrome Recruiting FRA 0
NCT03745716 Phase III APR-246 + Azacitidine Azacitidine APR-246 & Azacitidine for the Treatment of TP53 Mutant Myelodysplastic Syndromes (MDS) Completed USA | FRA 0
NCT03746041 Phase I Abaloparatide + Bevacizumab A Phase I Pilot Study of Abaloparatide + Bevacizumab in Myelodysplastic Syndromes Completed USA 0
NCT03770429 Phase I Ceralasertib AZD6738 for Patients With Progressive MDS or CMML Recruiting USA 0
NCT03772925 Phase I Belinostat + MLN4924 Pevonedistat and Belinostat in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Active, not recruiting USA 0
NCT03787498 Phase I PLX2853 A Study of PLX2853 in Relapsed or Refractory Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome Completed USA 0
NCT03807063 Phase I Rimiducid Rivogenlecleucel Rivogenlecleucel Donor Lymphocyte Immunotherapy in Treating Patients With Recurrent Blood Cancers After Stem Cell Transplant Withdrawn USA 0
NCT03814005 Phase I Azacitidine + MLN4924 A Study of Pevonedistat in Combination With Azacitidine in Participants With Higher-risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myelogenous Leukemia (AML) With Severe Renal Impairment or Mild Hepatic Impairment Completed USA | ESP 0
NCT03839771 Phase III Ivosidenib Enasidenib A Study of Ivosidenib or Enasidenib in Combination With Induction Therapy and Consolidation Therapy, Followed by Maintenance Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myedysplastic Syndrome EB2, With an IDH1 or IDH2 Mutation, Respectively, Eligible for Intensive Chemotherapy (HOVON150AML) Recruiting FRA | ESP | DEU | BEL | AUT | AUS 9
NCT03843528 Phase I Azacitidine + Vorinostat Vorinostat Dose-escalation After Allogeneic Hematopoietic Cell Transplantation Recruiting USA 0
NCT03862157 Phase Ib/II Azacitidine + MLN4924 + Venetoclax Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Active, not recruiting USA 0
NCT03884829 Phase I CYC140 A Phase I Study of CYC140, a PLK-1 Inhibitor, in Advanced Leukemias or MDS Recruiting USA 0
NCT03885947 Phase I Cyclophosphamide + Fludarabine + Thiotepa VPA Expanded UCB Transplantation for Treatment of Patients With Hematological Malignancies Completed USA 0
NCT03886662 Phase Ib/II LB-100 A Study of LB-100 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) Unknown status USA 0
NCT03886831 Phase I PRT543 A Study of PRT543 in Participants With Advanced Solid Tumors and Hematologic Malignancies Completed USA 0
NCT03896269 Phase I CPX-351 CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia Recruiting USA 0
NCT03912064 Phase I Ipilimumab A Phase 1 Trial of CD25/Treg-depleted DLI Plus Ipilimumab for Myeloid Disease Relapse After Matched-HCT Recruiting USA 0
NCT03913026 Phase II ECT-001 cord blood cells Mycophenolate mofetil Tacrolimus Cyclophosphamide + Fludarabine Cyclophosphamide + Fludarabine + Thiotepa UM171 Expanded Cord Blood In Patients With High-Risk Acute Leukemia/Myelodysplasia Active, not recruiting CAN 0
NCT03915379 Phase I JNJ-67571244 A Study of JNJ-67571244 in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) Completed USA | ESP | DEU 0
NCT03927261 Phase I PRGN-3006 PRGN-3006 Adoptive Cellular Therapy Relapsed or Refractory AML or High Risk MDS Recruiting USA 0
NCT03929211 Phase Ib/II CPI-613 + Hydroxychloroquine CPI-613 and Hydroxychloroquine for Patients With High Risk Myelodysplastic Syndrome Withdrawn USA 0
NCT03931291 Phase II APR-246 + Azacitidine APR-246 in Combination With Azacitidine for TP53 Mutated AML (Acute Myeloid Leukemia) or MDS (Myelodysplastic Syndromes) Following Allogeneic Stem Cell Transplant Completed USA 0
NCT03932643 Phase I ONC201 ONC 201 Maintenance Therapy in Acute Myeloid Leukemia and Myelodysplastic Syndrome After Stem Cell Transplant Active, not recruiting USA 0
NCT03940352 Phase I Siremadlin + Venetoclax Sabatolimab + Siremadlin HDM201 in Combination With MBG453 or Venetoclax in Patients With Acute Myeloid Leukemia (AML) or High-risk Myelodysplastic Syndrome (MDS) Active, not recruiting USA | ITA | ESP | DEU | AUS 2
NCT03946670 Phase II Decitabine + Sabatolimab Azacitidine Azacitidine + Sabatolimab Decitabine A Study of MBG453 in Combination With Hypomethylating Agents in Subjects With IPSS-R Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS). Active, not recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT 8
NCT03953898 Phase II Olaparib Using the Anticancer Drug Olaparib to Treat Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome With an Isocitrate Dehydrogenase (IDH) Mutation Active, not recruiting USA 0
NCT03957876 Phase II CPX-351 CPX-351 Therapy for MDS After Hypomethylating Agent Failure Recruiting USA 0
NCT03969446 Phase I Decitabine + Pembrolizumab Pembrolizumab and Decitabine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome That Is Newly-Diagnosed, Recurrent, or Refractory Recruiting USA 0
NCT03974217 Phase I Talazoparib Talazoparib for Cohesin-Mutated AML and MDS With Excess Blasts Recruiting USA 0
NCT04013880 Phase Ib/II Decitabine and Cedazuridine + Olutasidenib ASTX727 and FT-2102 in Treating IDH1-Mutated Recurrent/Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia Withdrawn 0
NCT04021368 Phase I RVU120 SEL120 in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome Active, not recruiting USA 1
NCT04022785 Phase I Azacitidine + PLX51107 PLX51107 and Azacitidine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Completed USA 0
NCT04027309 Phase III Midostaurin Gilteritinib A Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndromes With Excess Blasts-2 With FLT3 Mutations Eligible for Intensive Chemotherapy (HOVON 156 AML) Active, not recruiting FRA | ESP | DEU | BEL | AUT | AUS 8
NCT04047641 Phase II Quizartinib Cladribine + Cytarabine + Idarubicin + Quizartinib Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome Recruiting USA 0
NCT04055844 Phase II Decitabine + Ruxolitinib Multi-Ctr PII Cmb.Modality Tx Ruxolitinib, Decitabine, and DLI for Post HSCT in AML/MDS Completed USA 0
NCT04079296 Phase Ib/II ASP7517 A Study Investigating the Safety, Tolerability and Efficacy of ASP7517 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML) and Relapsed/Refractory Higher Risk Myelodysplastic Syndrome (MDS) Completed USA 1
NCT04092179 Phase Ib/II Enasidenib + Venetoclax Study of Enasidenib and Venetoclax in IDH2-Mutated Blood Cancers Terminated CAN 0
NCT04103879 Phase II ECT-001 cord blood cells Cyclophosphamide + Fludarabine + Thiotepa Tacrolimus Cyclophosphamide + Fludarabine Mycophenolate mofetil US Study of UM171-Expanded CB in Patients With High Risk Leukemia/Myelodysplasia Active, not recruiting USA 1
NCT04109482 Phase Ib/II Cyclophosphamide + Decitabine + Fludarabine + MB-102 Trial to Evaluate the Safety and Efficacy of MB-102 in Patients With BPDCN, AML, and hrMDS. Terminated USA 0
NCT04128020 Phase I Azacitidine + Nivolumab Nivolumab Azacitidine Plus Nivolumab Following Reduced-intensity Allogeneic PBSC Transplantation for Patients With AML and High-risk Myelodysplasia Withdrawn 0
NCT04128748 Phase Ib/II CPX-351 + Quizartinib Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome Recruiting USA 0
NCT04139434 Phase I LP-108 Dose-escalation Study of Oral Administration of LP-108 in Patients With Relapsed or Refractory Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML) Recruiting USA | ESP 0
NCT04140487 Phase Ib/II Azacitidine + Gilteritinib + Venetoclax Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplasm Active, not recruiting USA 0
NCT04146038 Phase II Decitabine + Salsalate + Venetoclax Azacitidine + Salsalate + Venetoclax Salsalate, Venetoclax, and Decitabine or Azacitidine for the Treatment of Acute Myeloid Leukemia or Advanced Myelodysplasia/Myeloproliferative Disease Completed USA 0
NCT04160052 Phase Ib/II Azacitidine + Venetoclax Venetoclax and Azacitidine for the Treatment of High-Risk Recurrent or Refractory Myelodysplastic Syndrome Recruiting USA 0
NCT04167696 Phase I CYAD-02 Cyclophosphamide + Fludarabine Study in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Patients to Determine the Recommended Dose of CYAD-02 (CYCLE-1) Recruiting USA | BEL 0
NCT04167917 Phase I NTX-301 NTX-301 in MDS/AML Recruiting USA 0
NCT04187703 Phase I Azacitidine + Decitabine 5-Azacitidine and Decitabine Epigenetic Therapy for Myeloid Malignancies Recruiting USA 0
NCT04227847 Phase I SEA-CD70 A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies Recruiting USA 1
NCT04239157 Phase II Azacitidine + Canakinumab Canakinumab and Azacitidine for the Treatment of Low or Intermediate Risk Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia Recruiting USA 0
NCT04243785 Phase I BTX-A51 A Study of BTX-A51 in People With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome Recruiting USA 0
NCT04245397 Phase I SX-682 SX-682 Treatment in Subjects With Myelodysplastic Syndrome Who Had Disease Progression or Are Intolerant to Prior Therapy Recruiting USA 0
NCT04256317 Phase III ASTX030 ASTX030 + Azacitidine ASTX030 + Azacitidine + Cedazuridine A Study of ASTX030 (Cedazuridine in Combination With Azacitidine) in MDS, CMML, or AML Recruiting USA 0
NCT04264806 Phase II ARGX-110 + Azacitidine Azacitidine A Study of Cusatuzumab in Combination With Azacitidine Compared With Azacitidine Alone in Patients With Higher-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) and Who Are Not Candidates for Hematopoietic Stem Cell Transplantation (HSCT) Withdrawn ITA | GBR | FRA | ESP | DEU | AUS 5
NCT04266301 Phase III Azacitidine Azacitidine + Sabatolimab Study of Efficacy and Safety of MBG453 in Combination With Azacitidine in Subjects With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2) (STIMULUS-MDS2) Active, not recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS 26
NCT04278768 Phase I CA-4948 An Open Label Dose Escalation Trial of CA-4948 in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome Recruiting USA | ITA | FRA | ESP | DEU 3
NCT04284228 Phase Ib/II Cyclophosphamide + Fludarabine + NEXI-001 T Cells Antigen-specific T Cell Therapy for AML or MDS Patients With Relapsed Disease After Allo-HCT Active, not recruiting USA 0
NCT04313881 Phase III Azacitidine Azacitidine + Hu5F9-G4 Magrolimab + Azacitidine Versus Azacitidine + Placebo in Untreated Participants With Myelodysplastic Syndrome (MDS) (ENHANCE) Terminated USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS 11
NCT04326764 Phase III Panobinostat Panobinostat Maintenance After HSCT fo High-risk AML and MDS Terminated DEU 1
NCT04361058 Phase I Nivolumab Nivolumab for High-Risk MDS/AML Patients After Allogeneic Stem Cell Transplant With Post-Transplant Cyclophosphamide Withdrawn USA 0
NCT04401748 Phase III Azacitidine + Venetoclax Azacitidine Safety And Efficacy Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Complete Remission and Overall Survival In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome (Verona) Active, not recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS 13
NCT04402541 Phase I CB-5339 Study of CB-5339 in Acute Myeloid Leukemia or Myelodysplastic Syndrome Completed USA | AUS 0
NCT04417517 Phase Ib/II Azacitidine + Evorpacept A Study of ALX148 With Azacitidine for Higher Risk Myelodysplastic Syndrome (ASPEN-02) Active, not recruiting USA | ESP 1
NCT04429191 Phase I JSP191 JSP191 Antibody Targeting Conditioning in MDS/AML Patients Undergoing Hematopoietic Cell Transplantation Unknown status USA 0
NCT04487106 Phase II Azacitidine + Trametinib + Venetoclax Azacitidine, Venetoclax, and Trametinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndrome Completed USA 0
NCT04493138 Phase Ib/II Azacitidine + Quizartinib Azacitidine and Quizartinib for the Treatment of Myelodysplastic Syndrome or Myelodysplastic/Myeloproliferative Neoplasm With FLT3 or CBL Mutations Recruiting USA 0
NCT04493164 Phase II CPX-351 + Ivosidenib Ivosidenib CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome Recruiting USA 0
NCT04522895 Phase II Enasidenib IDH2-Post-Allo-Trial for Patients With IDH2-mut Myeloid Neoplasms After Allo-SCT Active, not recruiting DEU 0
NCT04543305 Phase I PRT1419 A Study of PRT1419 in Patients With Relapsed/Refractory Hematologic Malignancies Completed USA 0
NCT04550442 Phase Ib/II Azacitidine + Venetoclax Venetoclax and Azacitidine for the Treatment of Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia Recruiting USA 0
NCT04581512 Phase Ib/II EP0042 Study to Evaluate the Safety and Tolerability of EP0042 Recruiting GBR | AUS 1
NCT04582864 Phase II Flotetuzumab Flotetuzumab for Relapsed Acute Myeloid Leukemia (AML) Following Allogeneic Hematopoietic Cell Transplantation (Allo-HCT) Recruiting USA 0
NCT04609826 Phase I JNJ74856665 Azacitidine + JNJ74856665 JNJ74856665 + Venetoclax A Study of JNJ-74856665 in Participants With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) Active, not recruiting GBR | FRA | ESP 1
NCT04623996 Phase Ib/II TP-0184 A Study of TP-0184 to Treat Anemia in Adults With IPSS-R Low or Intermediate Risk MDS Terminated USA 0
NCT04628026 Phase III Cytarabine + Idarubicin + Venetoclax Cytarabine + Idarubicin Etoposide + Mitoxantrone + Venetoclax Etoposide + Mitoxantrone Cytarabine + Venetoclax Cytarabine + Daunorubicin + Venetoclax Cytarabine + Daunorubicin Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Patients With Newly Diagnosed AML or MDS-EB-2 Recruiting DEU 0
NCT04639024 Phase II Camidanlumab tesirine ADCT-301 in Patients With R/R AML, MDS, or MDS/MPN Terminated USA 0
NCT04655755 Phase Ib/II Decitabine and Cedazuridine + Venetoclax Venetoclax in Combination With ASTX727 for the Treatment of Treatment-Naive High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia Recruiting USA 0
NCT04708054 Phase II Busulfan + Cladribine + Fludarabine + Thiotepa + Venetoclax Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS Active, not recruiting USA 0
NCT04712942 Phase II Azacitidine + MLN4924 Azacitidine Treatment of MDS/AML Patients With an Impending Hematological Relapse With AZA or ATA and Pevonedistat Completed DEU 0
NCT04730258 Phase Ib/II CFI-400945 CFI-400945 + Decitabine Azacitidine + CFI-400945 A Study of CFI-400945 With or Without Azacitidine or Decitabine in Patients With AML, MDS or CMML (TWT-202) Recruiting USA | CAN 1
NCT04734990 Phase Ib/II Azacitidine + Seclidemstat Seclidemstat and Azacitidine for the Treatment of Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia Recruiting USA 0
NCT04771130 Phase Ib/II Azacitidine + BGB-11417 A Study of BGB-11417 in Participants With Myeloid Malignancies Recruiting USA | ESP | DEU | AUS 3
NCT04797780 Phase III Azacitidine Azacitidine + Tamibarotene Tamibarotene Plus Azacitidine in Participants With Newly Diagnosed RARA-positive Higher-Risk Myelodysplastic Syndrome Recruiting USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUT 4
NCT04798339 Phase Ib/II Canakinumab + Darbepoetin Alfa Canakinumab With Darbepoetin Alfa in PTs With Lower-Risk MDS Who Have Failed ESA Recruiting USA 0
NCT04810611 Phase I NIS793 Sabatolimab Canakinumab + Sabatolimab NIS793 + Sabatolimab Canakinumab Phase Ib Study of Select Drug Combinations in Patients With Lower Risk MDS Active, not recruiting USA | ITA | ESP | AUS 3
NCT04812548 Phase II Azacitidine + Sabatolimab + Venetoclax A Study of Sabatolimab in Combination With Azacitidine and Venetoclax in High or Very High Risk MDS Participants (STIMULUS-MDS3) Completed ITA | FRA | ESP | DEU | BEL 2
NCT04823624 Phase II Sabatolimab MBG453 in Lower Risk MDS Recruiting USA 0
NCT04874194 Phase Ib/II Omacetaxine mepesuccinate + Venetoclax Omacetaxine and Venetoclax for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Harboring Mutant RUNX1 Recruiting USA 0
NCT04878432 Phase II Azacitidine + Decitabine and Cedazuridine + Sabatolimab Azacitidine + Decitabine + Sabatolimab STIMULUS MDS-US : Sabatolimab Added to HMA in Higher Risk MDS Recruiting USA 0
NCT04891757 Phase I FHD-286 FHD-286 in Subjects With Advanced Hematologic Malignancies Recruiting USA 0
NCT04912063 Phase I Azacitidine + Lemzoparlimab Azacitidine + Lemzoparlimab + Venetoclax Study to Evaluate Adverse Events and Movement of Lemzoparlimab in Body When Used Intravenously (IV) With Azacitidine Subcutaneously or IV and Venetoclax Orally in Participants With Acute Myeloid Leukemia and With Azacitdine With or Without Venetoclax in Participants With Myelodysplastic Syndrome Terminated USA | ITA | ESP | DEU | AUS 2
NCT04937166 Phase I Azacitidine + DSP107 + Venetoclax A Study of Dual-SIgnaling Protein 107 (DSP107) for Patients With Hematological Malignancies Recruiting USA 0
NCT04951778 Phase I CC-91633 Study to Evaluate Safety and Tolerability of CC-91633 (BMS-986397) in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-Risk Myelodysplastic Syndromes Recruiting USA | GBR | ESP | CAN | AUS 0
NCT04953780 Phase I Calaspargase pegol-mknl + Cytarabine + Idarubicin 2157GCCC:Phase 1 of Calaspargase Pegol-mknl w/ Cytarabine and Idarubicin in Newly Dx AML Recruiting USA 0
NCT04964518 Phase I APG-2575 + Azacitidine A Study of APG-2575 in Combination With Azacitidine in Patients With Acute Myeloid Leukemia (AML) Recruiting USA | AUS 0
NCT05005299 Phase I Cyclophosphamide + Fludarabine + Venetoclax Venetoclax in Combination With Non-myeloablative Conditioning Allogeneic Haematopoietic Stem Cell Transplantation (VICTORY) Recruiting AUS 0
NCT05010122 Phase Ib/II Decitabine and Cedazuridine + Gilteritinib + Venetoclax ASTX727, Venetoclax, and Gilteritinib for the Treatment of Newly Diagnosed, Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome Recruiting USA 0
NCT05024994 Phase II E7820 A Study of E7820 in People With Bone Marrow (Myeloid) Cancers Active, not recruiting USA 0
NCT05030675 Phase I Fostamatinib Fostamatinib for the Treatment of Lower-risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia Who Have Failed Therapy With Hypomethylating Agents Recruiting USA 0
NCT05086315 Phase Ib/II SAR443579 First-in-human Study of SAR443579 Infusion in Male and Female Participants of at Least 12 Years of Age With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-cell Acute Lymphoblastic Leukemia (B-ALL) or High Risk-myelodysplasia (HR-MDS) Recruiting USA | FRA | AUS 1
NCT05107856 Phase I PRT1419 A Study of PRT1419 Injection in Patients With Relapsed/Refractory Hematologic Malignancies Terminated USA 0
NCT05146739 Phase I Cytarabine + Fludarabine + Uproleselan Highest Dose of Uproleselan in Combination With Fludarabine and Cytarabine for Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Mixed Phenotype Acute Leukemia Relapsed or Refractory and That Expresses E-selectin Ligand on the Cell Membrane Recruiting USA 0
NCT05148234 Phase Ib/II BMS-986253 + Decitabine and Cedazuridine BMS-986253 A Phase I/II Trial of BMS-986253 in Myelodysplastic Syndromes Active, not recruiting USA 0
NCT05168202 Phase I Azacitidine + CC-95251 CC-95251 A Study to Assess the Effect of CC-95251 in Participants With Acute Myeloid Leukemia and Myelodysplastic Syndromes Recruiting USA | ITA | GBR | FRA | ESP | CAN | AUS 2
NCT05168904 Phase Ib/II CYC065 A Study to Investigate Fadraciclib (CYC065), in Subjects With Leukemia or Myelodysplastic Syndrome (MDS) Suspended USA 0
NCT05178342 Phase II CA-4948 Treatment of Anemia in Patients With Very Low, Low or Intermediate Risk Myelodysplastic Syndromes With CA-4948 (LUCAS) Recruiting DEU 0
NCT05209152 Phase I AMG 176 + Azacitidine AMG 176 AMG 176 With Azacitidine in Subjects With Myelodysplastic Syndrome /Chronic Myelomonocytic Leukemia Completed USA 0
NCT05275439 Phase I Azacitidine + SL-172154 + Venetoclax Azacitidine + SL-172154 SL-172154 Phase 1 Study of Shattuck Labs (SL)-172154 in Subjects With MDS or AML Recruiting USA | GBR | CAN 0
NCT05282459 Phase Ib/II Enasidenib Enasidenib in MDS &Non-proliferative Chronic Myelomonocytic Leukemia w/o IDH2 Mutation Recruiting USA 0
NCT05292664 Phase I Azacitidine + Cytarabine + Hydrocortisone + Leucovorin + Methotrexate + Venetoclax Calaspargase pegol-mknl + Cytarabine + Dexamethasone + Dexrazoxane + Doxorubicin + Hydrocortisone + Leucovorin + Methotrexate + Venetoclax + Vincristine Sulfate Azacitidine + Venetoclax Venetoclax Basket Trial for High Risk Hematologic Malignancies Recruiting USA 0
NCT05308264 Phase Ib/II R289 Study of R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS) Recruiting USA 0
NCT05362773 Phase I MGD024 A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies Recruiting USA 0
NCT05365035 Phase II Azacitidine + Venetoclax Cladribine + Cytarabine + Venetoclax A Phase II Study of Cladribine and Low Dose Cytarabine in Combination With Venetoclax, Alternating With Azacitidine and Venetoclax, in Patients With Higher-risk Myeloproliferative Chronic Myelomonocytic Leukemia or Higher-risk Myelodysplastic Syndromes With Excess Blasts Recruiting USA 0
NCT05379166 Phase II Azacitidine + Venetoclax Venetoclax and Azacitidine for Treatment of Therapy Related or Secondary Myelodysplastic Syndrome Recruiting USA 0
NCT05400122 Phase I Aldesleukin + Vactosertib Cyclophosphamide + Fludarabine Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer Suspended USA 0
NCT05424380 Phase I GSK3745417 A Phase 1, Open Label Study of Intravenous GSK3745417 to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Determine RP2D & Schedule in Participants With Relapsed or Refractory Myeloid Malignancies Including AML and HR MDS Active, not recruiting ITA | ESP | DEU | CAN 1
NCT05428969 Phase Ib/II Azacitidine + FP-1305 Azacitidine + FP-1305 + Venetoclax A Study to Assess Safety, Tolerability and Preliminary Efficacy of Bexmarilimab in Combination With Standard of Care in Patients With Hematological Malignancies (BEXMAB) Recruiting USA 1
NCT05455294 Phase I Decitabine + Navitoclax + Venetoclax Combination Navitoclax, Venetoclax and Decitabine for Advanced Myeloid Neoplasms Recruiting USA 0
NCT05476770 Phase I Cytarabine + Hydrocortisone + Methotrexate + Tagraxofusp-erzs Cytarabine + Dexamethasone + Hydrocortisone + Methotrexate + Tagraxofusp-erzs + Vincristine Sulfate Azacitidine + Cytarabine + Hydrocortisone + Methotrexate + Tagraxofusp-erzs Cytarabine + Fludarabine + Hydrocortisone + Methotrexate + Tagraxofusp-erzs Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies Recruiting USA | AUS 0
NCT05564650 Phase Ib/II Decitabine + Navitoclax + Venetoclax Evaluating Navitoclax After Failure of Standard Treatments of Azacitidine or Decitabine and Venetoclax in Patients With Aggressive Myelodysplastic Syndrome Recruiting USA 0
NCT05583552 Phase II Imetelstat Study to Evaluate Imetelstat in Patients With High-Risk MDS or AML Failing HMA-based Therapy (IMpress) Recruiting FRA | DEU | AUS 0
NCT05601726 Phase I ABD-3001 First-in-human Study Aiming to Characterize the Safety, Tolerability, Pharmacokinetic and Preliminary Signs of Activity of ABD-3001 in Refractory or Relapsed AML and High Risk MDS Adult Patients (ODYSSEY) Active, not recruiting FRA 0
NCT05636514 Phase I Decitabine and Cedazuridine + Defactinib Combined Evaluation of Epigenetic and Sensitising Therapy in AML and MDS (CELESTIAL-MDS) Recruiting AUS 0
NCT05673057 Phase Ib/II MP0533 Study of MP0533 in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Recruiting FRA 3
NCT05732103 Phase Ib/II CTX-712 A Study of CTX-712 in Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes Recruiting USA 0
NCT05756322 Phase Ib/II LBS-007 The Safety and Tolerability of LBS-007 in Patients With Relapsed or Resistant Acute Leukaemias Recruiting AUS 1
NCT05775406 Phase I KT-253 Safety and Clinical Activity of KT-253 in Adult Patients With High Grade Myeloid Malignancies, Acute Lymphocytic Leukemia, Lymphoma, Solid Tumors Recruiting USA 0
NCT05782127 Phase Ib/II Azacitidine + Venetoclax Oral Azacitidine Combined With Venetoclax in Previously Untreated Higher-risk Myelodysplastic Syndromes Not yet recruiting FRA 0
NCT05787496 Phase I NC525 A Safety, Tolerability and Efficacy Study of NC525 in Subjects With Advanced Myeloid Neoplasms Recruiting USA 0
NCT05823571 Phase I Itacitinib Itacitinib With High-dose Posttransplantation Cyclophosphamide in Older Patients Recruiting USA 0
NCT05829226 Phase I LYT-200 A Phase 1 Study With LYT-200 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML), or With Relapsed/Refractory, High-risk Myelodysplastic Syndrome (MDS) Recruiting USA 0
NCT05834244 Phase I Azacitidine + Venetoclax A Phase Ib Trial of Azacitidine, Venetoclax and Allogeneic NK Cells for Acute Myeloid Leukemia (ADVENT-AML) Recruiting USA 0
NCT05835011 Phase II Decitabine and Cedazuridine + Hu5F9-G4 A Study of Oral Decitabine/Cedazuridine in Combination With Magrolimab in Participants With Intermediate- to Very High-Risk Myelodysplastic Syndromes (MDS) Terminated USA 0
NCT05903274 Phase I JSP191 JSP191 (Briquilimab) in Subjects With LR-MDS Recruiting USA 0
NCT05918055 Phase Ib/II Decitabine and Cedazuridine + KPT-8602 Eltanexor (KPT-8602) With Inqovi (Decitabine-Cedazuridine) in High-Risk Myelodysplastic Syndromes Recruiting USA 0
NCT05933070 Phase I INKmune A Phase I Open-Label Dose Escalation Study of Intravenous INKmune In Patients With MDS or AML (LAUREL) Recruiting GBR 1
NCT05955261 Phase II Azacitidine + Cytarabine + Daunorubicin + Etoposide + Fludarabine + Gemtuzumab ozogamicin + Gilteritinib + Idarubicin + Venetoclax Cytarabine + Daunorubicin + Etoposide + Fludarabine + Gemtuzumab ozogamicin + Gilteritinib + Idarubicin + mitoxantrone hydrochloride + Venetoclax Cytarabine + Daunorubicin + Etoposide + Gemtuzumab ozogamicin + Gilteritinib + mitoxantrone hydrochloride + Venetoclax A Study of Venetoclax in Combination With Conventional Chemotherapy in Pediatric Patients With Acute Myeloid Leukemia Recruiting USA 0
NCT05961839 Phase I SGR-2921 Study of SGR-2921 in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Recruiting USA 0
NCT06034275 Phase I VIP943 Study of VIP943 in Subjects With Advanced CD123 pos Hematologic Malignancies Recruiting USA 0
NCT06129734 Phase Ib/II Decitabine + Venetoclax Decitabine and Venetoclax Treatment as Maintenance Therapy in Patients Post Allograft Stem Cell Transplant Not yet recruiting USA 0
NCT06146257 Phase I GLB-001 A Study of GLB-001 in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher Risk Myelodysplastic Syndromes Recruiting USA 0
NCT06179511 Phase Ib/II AZD9829 Study of AZD9829 in CD123+ Hematological Malignancies Recruiting USA | ITA | ESP | DEU | AUS 4
NCT06284460 Phase Ib/II ASTX029 ASTX029 + Decitabine and Cedazuridine Phase I/II Study of a Combination of Decitabine and Cedazuridine (ASTX727) and ASTX029, an ERK Inhibitor, for Patients With RAS Pathway Mutant Myelodysplastic Syndromes and Myelodysplastic/Myeloproliferative Neoplasms Not yet recruiting USA 0
NCT06285890 Phase I Azacitidine + HC-7366 + Venetoclax Phase I Study of HC-7366 With Azacitidine and Venetoclax for Acute Myeloid Leukemia Not yet recruiting USA 0
NCT06287944 Phase I Melphalan Fludarabine Sirolimus 225Ac-DOTA-Daratumumab Tacrolimus 225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome Not yet recruiting USA 0
NCT06291987 Phase I Ivosidenib + Ruxolitinib Ivosidenib and Ruxolitinib in Patients With Advanced Blood Cancers That Have IDH1 Gene MutationPhase MPNs (MPN) Not yet recruiting USA 0
NCT06297941 Phase I REM-422 Study of REM-422 in Patients With AML or Higher Risk MDS Not yet recruiting USA 0